A detailed history of Ubs Group Ag transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 41,604 shares of ACET stock, worth $37,443. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,604
Previous 160,835 74.13%
Holding current value
$37,443
Previous $194,000 69.59%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.07 - $1.63 $127,577 - $194,346
-119,231 Reduced 74.13%
41,604 $59,000
Q2 2024

Aug 13, 2024

BUY
$1.21 - $2.4 $129,829 - $257,512
107,297 Added 200.41%
160,835 $194,000
Q1 2024

May 13, 2024

BUY
$1.76 - $3.45 $54,489 - $106,812
30,960 Added 137.12%
53,538 $125,000
Q4 2023

Feb 09, 2024

BUY
$1.11 - $1.89 $20,247 - $34,475
18,241 Added 420.59%
22,578 $42,000
Q3 2023

Nov 09, 2023

BUY
$1.37 - $3.4 $5,904 - $14,654
4,310 Added 15962.96%
4,337 $5,000
Q2 2023

Aug 11, 2023

BUY
$2.13 - $7.13 $57 - $192
27 New
27 $0
Q4 2022

Feb 08, 2023

BUY
$7.72 - $21.27 $774,470 - $2.13 Million
100,320 Added 580.93%
117,589 $1.05 Million
Q3 2022

Nov 10, 2022

BUY
$13.43 - $18.74 $231,922 - $323,621
17,269 New
17,269 $246,000
Q2 2022

Aug 10, 2022

SELL
$10.26 - $20.81 $5,612 - $11,383
-547 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$11.53 - $19.97 $107,667 - $186,479
-9,338 Reduced 94.47%
547 $11,000
Q4 2021

Feb 14, 2022

BUY
$7.37 - $17.49 $71,732 - $170,230
9,733 Added 6403.29%
9,885 $173,000
Q3 2021

Nov 15, 2021

BUY
$6.29 - $9.93 $956 - $1,509
152 New
152 $1,000
Q2 2021

Aug 13, 2021

SELL
$9.19 - $15.93 $15,558 - $26,969
-1,693 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$12.12 - $17.17 $13,562 - $19,213
1,119 Added 194.95%
1,693 $22,000
Q4 2020

Feb 11, 2021

SELL
$10.36 - $14.77 $8,557 - $12,200
-826 Reduced 59.0%
574 $8,000
Q3 2020

Nov 12, 2020

BUY
$10.18 - $21.4 $14,252 - $29,959
1,400 New
1,400 $17,000

Others Institutions Holding ACET

About Adicet Bio, Inc.


  • Ticker ACET
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,030,800
  • Market Cap $36M
  • Description
  • Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
More about ACET
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.